![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAP7D2 |
Gene summary for MAP7D2 |
![]() |
Gene information | Species | Human | Gene symbol | MAP7D2 | Gene ID | 256714 |
Gene name | MAP7 domain containing 2 | |
Gene Alias | MAP7D2 | |
Cytomap | Xp22.12 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96T17 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256714 | MAP7D2 | C43 | Human | Oral cavity | OSCC | 2.05e-28 | 6.15e-01 | 0.1704 |
256714 | MAP7D2 | C46 | Human | Oral cavity | OSCC | 3.19e-03 | 8.29e-02 | 0.1673 |
256714 | MAP7D2 | LN22 | Human | Oral cavity | OSCC | 4.06e-06 | 7.92e-01 | 0.1733 |
256714 | MAP7D2 | LN38 | Human | Oral cavity | OSCC | 8.69e-03 | 4.00e-01 | 0.168 |
256714 | MAP7D2 | LN46 | Human | Oral cavity | OSCC | 1.74e-05 | 2.94e-01 | 0.1666 |
256714 | MAP7D2 | SYSMH1 | Human | Oral cavity | OSCC | 5.62e-06 | 1.10e-01 | 0.1127 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP7D2 | SNV | Missense_Mutation | c.593N>C | p.Arg198Pro | p.R198P | Q96T17 | protein_coding | tolerated(0.15) | probably_damaging(0.929) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
MAP7D2 | SNV | Missense_Mutation | rs768092526 | c.410N>A | p.Arg137His | p.R137H | Q96T17 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-A2-A1FX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508A>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508A>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508N>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508N>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MAP7D2 | SNV | Missense_Mutation | novel | c.1632N>A | p.Met544Ile | p.M544I | Q96T17 | protein_coding | tolerated(0.39) | benign(0.022) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508A>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-B6-A1KI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508N>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP7D2 | SNV | Missense_Mutation | rs764261929 | c.1508N>G | p.Glu503Gly | p.E503G | Q96T17 | protein_coding | deleterious(0.03) | benign(0.23) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |